Bepranemab

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
5	進行性核上性麻痺	2

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04658199 (ClinicalTrials.gov)	November 16, 2020	1/12/2020	A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participant ...	An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administr ...	Progressive Supranuclear Palsy	Drug: UCB0107 (bepranemab)	UCB Biopharma SRL	NULL	Active, not recruiting	40 Years	N/A	All	19	Phase 1	Belgium;Germany;Spain;United Kingdom
2	NCT04185415 (ClinicalTrials.gov)	December 3, 2019	2/12/2019	A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supran ...	A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, ...	Progressive Supranuclear Palsy	Drug: bepranemab;Drug: Placebo	UCB Biopharma SRL	NULL	Completed	40 Years	N/A	All	25	Phase 1	Belgium;Germany;Spain;United Kingdom

First Previous1Next Last